Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Alligator, Bioscience

Alligator Bioscience Sweden

16.09.2020 - 08:43:53

Alligator Bioscience receives patent approval for the drug candidate ATOR-1015

The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on September 16, 2020.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes five lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/alligator-bioscience/r/alligator-bioscience-receives-patent-approval-for-the-drug-candidate-ator-1015,c3194695

The following files are available for download:

https://mb.cision.com/Main/12681/3194695/1306686.pdf

Alligator Bioscience receives patent approval for the drug candidate ATOR-1015

 

@ prnewswire.co.uk